In vitro investigation of inhalation delivery of nebulized liposomes

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26210%2F22%3APU146718" target="_blank" >RIV/00216305:26210/22:PU146718 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
In vitro investigation of inhalation delivery of nebulized liposomes
Original language description
Inhalation therapy is a promising way of drug delivery, but the suitable carrier system plays an important role in its effectiveness. The inhalation administration of two nebulized liposomal systems was investigated in this study. The first system contained dipalmitoylfosfatidylcholine (DPPC), polyethylene glycol (PEG) bonded to dipalmitoylphosphoethanolamine (DPPE), and cholesterol (Chol). The second one consisted of DPPC, phosphatidic acid (PA), and Chol. These systems were nebulized by 2 air-jet nebulizers (AJN): Pari LC Sprint, and Pari LC Sprint Star. The stability during nebulization was assessed for both systems and both nebulizers. Aerodynamic Particle Size Distribution (APSD) of nebulized aerosols was measured. According to the results of the stability and APSD (MMADLC_Sprint_Star 7.39 ± 0.24 µm; MMADLC_Sprint 9.79 ± 0.41 µm), the air-jet nebulizer PARI LC Sprint Star and DPPC-PA-Chol liposomal system were selected as the most promising choice among the tested cases. This combination was used
Czech name
—
Czech description
—

Project
<a href="/en/project/GA22-20357S" target="_blank" >GA22-20357S: Measurement and computational simulation of transport of fibrous aerosols in high velocity gradient flow and interaction of fibres with a wall</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)